GSK and Ionis announced positive topline results from pivotal B‑Well 1 and B‑Well 2 Phase 3 studies of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B that aims for a functional cure. The companies said the trials met primary endpoints and that global regulatory filings are planned, marking a potential shift from lifelong suppression to finite therapy. Ionis and GSK will pursue filings based on the trials; public statements stressed the statistical and clinical significance of functional cure rates observed across study arms. The partnership underscores the maturation of RNA‑based antivirals and the strategic value of oligonucleotide platforms. If regulators approve, bepirovirsen could change treatment paradigms in HBV and prompt competitors to accelerate combination and cure‑focused programs.